Literature DB >> 1698442

Analysis of the c-Ha-ras-1 gene for deletion, mutation, amplification and expression in lymph node metastases of human head and neck carcinomas.

Z M Sheng1, M Barrois, J Klijanienko, C Micheau, J M Richard, G Riou.   

Abstract

The c-Ha-ras gene was analysed by Southern blot hybridisation in 67 specimens of lymph node metastases and in 25 specimens of primary tumours obtained from 85 untreated patients with head and neck squamous cell carcinoma. The loss of one c-Ha-ras allele was observed in 10/46 (22%) tumours from heterozygous patients for this locus. Different genes, located as the c-Ha-ras gene on the short arm of chromosome 11, were also found to be deleted suggesting that the deletion of other genes could play a role in aggressiveness of head and neck carcinomas. Using polymerase chain reaction, mutation at codon 12 was detected in only 2/54 (3.8%) tumours but no mutation involving codon 61 was found. Neither gene amplification nor gene rearrangement could be observed. Total RNA was prepared from 79 of these tumour specimens and analysed by Northern and slot blot hybridisation. A 1.2 kb c-Ha-ras transcript band was detected in all the RNA preparations. Relatively high c-Ha-ras transcript levels were found in 18% of lymph node metastases and in 21% of primary tumours, indicating no significant differences between these cancers. Moreover, the c-Ha-ras mRNA levels were not significantly greater in the primary tumours than in the normal mucosae in 10/12 cases for which both tissues were analysed. These data indicate that c-Ha-ras gene does not seem to be strongly involved in head and neck carcinomas at that advanced stage of the disease, as this was previously reported for earlier clinical stages.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1698442      PMCID: PMC1971465          DOI: 10.1038/bjc.1990.306

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  40 in total

1.  Somatic deletions and mutations of c-Ha-ras gene in human cervical cancers.

Authors:  G Riou; M Barrois; Z M Sheng; P Duvillard; C Lhomme
Journal:  Oncogene       Date:  1988-09       Impact factor: 9.867

2.  Partial nucleotide sequence of human calcitonin precursor mRNA identifies flanking cryptic peptides.

Authors:  R K Craig; L Hall; M R Edbrooke; J Allison; I MacIntyre
Journal:  Nature       Date:  1982-01-28       Impact factor: 49.962

3.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.

Authors:  D J Slamon; G M Clark; S G Wong; W J Levin; A Ullrich; W L McGuire
Journal:  Science       Date:  1987-01-09       Impact factor: 47.728

4.  Expression of p21ras in normal and malignant human tissues: lack of association with proliferation and malignancy.

Authors:  P G Chesa; W J Rettig; M R Melamed; L J Old; H L Niman
Journal:  Proc Natl Acad Sci U S A       Date:  1987-05       Impact factor: 11.205

5.  Prognostic significance of the expression of a ras protein with a molecular weight of 21,000 by human breast cancer.

Authors:  T Clair; W R Miller; Y S Cho-Chung
Journal:  Cancer Res       Date:  1987-10-15       Impact factor: 12.701

6.  Expression of Ha-ras oncogene products in human neuroblastomas and the significant correlation with a patient's prognosis.

Authors:  T Tanaka; D J Slamon; H Shimoda; C Waki; Y Kawaguchi; Y Tanaka; N Ida
Journal:  Cancer Res       Date:  1988-02-15       Impact factor: 12.701

7.  Detection of activated ras oncogenes in human thyroid carcinomas.

Authors:  H G Suárez; J A Du Villard; B Caillou; M Schlumberger; M Tubiana; C Parmentier; R Monier
Journal:  Oncogene       Date:  1988-04       Impact factor: 9.867

8.  Expression of p21ras in fresh primary and metastatic human colorectal tumors.

Authors:  G E Gallick; R Kurzrock; W S Kloetzer; R B Arlinghaus; J U Gutterman
Journal:  Proc Natl Acad Sci U S A       Date:  1985-03       Impact factor: 11.205

9.  Expression of ras proto-oncogene proteins in normal human tissues.

Authors:  M E Furth; T H Aldrich; C Cordon-Cardo
Journal:  Oncogene       Date:  1987-03       Impact factor: 9.867

10.  Immunocytochemical demonstration of p21 ras family oncogene product in normal mucosa and in premalignant and malignant tumours of the colorectum.

Authors:  I B Kerr; F D Lee; M Quintanilla; A Balmain
Journal:  Br J Cancer       Date:  1985-11       Impact factor: 7.640

View more
  12 in total

1.  Immunohistochemical Expression of N-ras Oncogene is a Late Event in Head and Neck Carcinomas.

Authors:  John S McDonald; Keith M Wilson; Peter Gartside; Robert L Sonke; Ljiljana Pavelic; Eric Okum; Julie Neanen; Jack L Gluckman; Zlatko P Pavelic
Journal:  Pathol Oncol Res       Date:  1996       Impact factor: 3.201

2.  Changes in expression of oncogenes and TP53 tumour suppressor gene as biomarkers in head and neck cancers.

Authors:  István Szanyi; Miklós Bauer; Imre Gerlinger; Tamás Járai; Gyula Gobel; László Lujber; Eva Szabadi; Katalin Fehér; Agoston Émber; István Ember; István Kiss
Journal:  Eur Arch Otorhinolaryngol       Date:  2010-12-01       Impact factor: 2.503

Review 3.  Protein-intrinsic and signaling network-based sources of resistance to EGFR- and ErbB family-targeted therapies in head and neck cancer.

Authors:  Ranee Mehra; Ilya G Serebriiskii; Roland L Dunbrack; Matthew K Robinson; Barbara Burtness; Erica A Golemis
Journal:  Drug Resist Updat       Date:  2011-09-14       Impact factor: 18.500

Review 4.  The role of oncogenes and tumour-suppressor genes in the aetiology of oral, head and neck squamous cell carcinoma.

Authors:  J K Field
Journal:  J R Soc Med       Date:  1995-01       Impact factor: 5.344

Review 5.  Anti-epidermal growth factor receptor therapy in head and neck squamous cell carcinoma: focus on potential molecular mechanisms of drug resistance.

Authors:  Carolien Boeckx; Marc Baay; An Wouters; Pol Specenier; Jan B Vermorken; Marc Peeters; Filip Lardon
Journal:  Oncologist       Date:  2013-07-02

Review 6.  Molecular and cellular biomarkers for field cancerization and multistep process in head and neck tumorigenesis.

Authors:  V A Papadimitrakopoulou; D M Shin; W K Hong
Journal:  Cancer Metastasis Rev       Date:  1996-03       Impact factor: 9.264

7.  The absence of Harvey ras mutations during development and progression of squamous cell carcinomas of the head and neck.

Authors:  L J Clark; K Edington; I R Swan; K A McLay; W J Newlands; L C Wills; H A Young; P W Johnston; R Mitchell; G Robertson
Journal:  Br J Cancer       Date:  1993-09       Impact factor: 7.640

8.  Expression of anionic glutathione S transferase (GST pi) gene in carcinomas of the uterine cervix and in normal cervices.

Authors:  G Riou; M Barrois; D Zhou
Journal:  Br J Cancer       Date:  1991-02       Impact factor: 7.640

9.  Expression of ras oncogene p21 protein in normal and neoplastic laryngeal tissues: correlation with histopathological features and epidermal growth factor receptors.

Authors:  G Scambia; L Catozzi; P Benedetti Panici; G Ferrandina; G Almadori; G Paludetti; G Cadoni; M Distefano; A Piffanelli; S Mancuso
Journal:  Br J Cancer       Date:  1994-06       Impact factor: 7.640

10.  Elevated P53 expression correlates with a history of heavy smoking in squamous cell carcinoma of the head and neck.

Authors:  J K Field; D A Spandidos; A Malliri; J R Gosney; M Yiagnisis; P M Stell
Journal:  Br J Cancer       Date:  1991-09       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.